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Purpose. Assess the aqueous humor ﬂare in transthyretin V30M amyloidosis patients (ATTRV30M).Materials and Methods. &is
is a retrospective, cross-sectional, noninterventional comparative study including 28 ATTRV30M patients with a unilateral
scalloped iris. For comparative analysis, the fellow eye, the nonscalloped iris eye, from each patient was used as control. All
patients underwent aqueous humor ﬂare meter and intraocular pressure (IOP) measurements. Results. Mean aqueous humor ﬂare
was signiﬁcantly higher in the eyes with the scalloped iris than the control group with the nonscalloped iris (14.1± 2.2 versus 6.5±
0.9 pc/ms, respectively). No signiﬁcant diﬀerences in IOP were found in the scalloped iris eyes than those in the nonscalloped iris
control group (17.1± 0.8 versus 16.8± 0.7mmHg, respectively). No signiﬁcant correlation was not found between the ﬂare and the
IOP value within groups.Conclusions. In this study, aqueous humor ﬂare values in the scalloped iris eyes may be a valid marker for
controlling the stage of the oculopathy in ATTRV30M patients.
1. Introduction
Hereditary transthyretin V30M amyloidosis (ATTRV30M)
is an autosomal dominant disorder and is a very common
form of hereditary amyloidosis caused by extracellular de-
position of variants of transthyretin (TTR) in several tissues,
including the eye [1, 2]. More than 100 amyloidogenic TTR
mutations have been documented [3], but in the Portuguese
type, the variant TTR has a substitution of methionine for
valine at position 30. Despite the worldwide distribution of
the disease, Portugal remains the main geographic focus of
amyloidosis TTR V30M [4]. ATTRV30M patients are
usually classiﬁed as presenting an early onset disease (onset
before 50 years of age) or a late-onset disease (onset after
50 years of age). Early onset is associated with a more ag-
gressive, rapidly progressing disease, especially if symptoms
appear before 40 years of age [5]. Most Portuguese
ATTRV30M patients are early-onset cases, with a worse
prognosis regarding the severity of symptoms and an ex-
pected survival of 10 to 15 years without treatment. Liver
transplantation is one of the treatments for ATTRV30M
amyloidosis as it removes circulating mutant TTR and in-
terrupts the progression of the disease and improve survival
and quality of life [6]. Tafamidis, an oral, non-NSAID, highly
speciﬁc TTR stabilizer has emerged as the new standard of
care for ATTRV30M and remains the only medicine ap-
proved for the treatment of transthyretin amyloidosis in
adult patients with stage 1 symptomatic polyneuropathy [7].
Nevertheless, the intraocular production of TTRV30Mby
the retinal and ciliary pigment epithelium remains un-
changed, contributing to the progression of amyloid
deposition-associated ocular manifestations such as abnormal
conjunctival vessels, dry eye, scalloped pupils, deposition of
amyloid on the anterior surface of the lens and on the pupil
border, vitreous amyloidosis, glaucoma, and retinal angiop-
athy. Moreover, their prevalence increases over time [8].
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Glaucoma is an ocular neurodegenerative disease and one
of the most common causes of blindness worldwide [9]. It is
characterized by retinal ganglion cell degeneration which can
lead to optic atrophy and visual ﬁeld defects [10]. Multiple
factors play a role in the etiology and pathology of the disease,
being intraocular pressure (IOP) the most important risk
factor usually caused by abnormal aqueous humor outﬂow
[11]. Extensive research over the last decade has shown that
no amyloid secondary glaucomatous proteomics and oxi-
dative damage can also lead to unfavourable eﬀects on the
trabecular meshwork and increased resistance to intraocular
aqueous humor drainage [11–19]. Moreover, assessments of
the involvement of ATTRV30M in ocular complications
showed that glaucoma was strongly associated with the
presence of scalloped iris [20]. Still, the nature of the in-
teraction mechanism of iris deformation and aqueous humor
ﬂow was not evaluated and is not fully understood yet [8, 21].
However, the presence of scalloped iris before the onset of
glaucoma was also observed [20]. Laser ﬂare cell meter is an
objective, sensitive, and noninvasive method for evaluating
the aqueous ﬂare and allows a quantitative assessment of
anterior chamber inﬂammation and breakdown of the blood-
aqueous barrier [22–24]. Several studies have shown altered
ﬂare values in glaucomatous eyes and speculated the role of
the anterior chamber aqueous ﬂare in predicting the risk of
glaucoma [25–30]. &erefore, the aim of this analysis is to
assess the blood-aqueous barrier (BAB) function with the use
of a laser ﬂare meter in ATTRV30M Portuguese patients with
and without scalloped iris.
2. Materials and Methods
&is was a retrospective, cross-sectional, noninterventional
study conducted at the Ophthalmic Department from
Centro Hospitalar do Porto, Porto. Written informed
consent was obtained from all patients. &is study was
performed in accordance with the Declaration of Helsinki of
the World Medical Association and was approved by the
Ethics Committee of the Centro Hospitalar do Porto.
2.1. Patients. &e study included a retrospective cohort of 28
consecutive patients (60.7%men;mean age: 46.5 (35–61) years)
examined for ocular abnormalities at the Ophthalmology
Service of Centro Hospitalar do Porto. All patients had the
ATTR V30M mutation conﬁrmed by genetic analysis and
presented unilateral scalloped iris. &ese patients presented in
both eyes no abnormalities in optic nerve and visual ﬁeld nor
ongoing treatment with ocular hypotensive eyedrops and/or
previous glaucoma or ocular surgery. &e only ocular treat-
ment was artiﬁcial tears, and all eyes had best corrected visual
acuity of 1.0 (Snellen equivalent). For comparative analysis, the
fellow eye, the nonscalloped iris eye, from each patient was used
as control. Data collection was from patients’ medical records
and included demographic data summarized in Table 1.
2.2. Measurement of Blood-Aqueous Barrier Function. To
clarify the relationship between IOP increase and the blood-
aqueous barrier function in both scalloped iris eyes and
nonscalloped iris eyes (control), we measured the IOP values
by using Goldmann applanation tonometry and the anterior
chamber ﬂare. Flare values were measured quantitatively by
laser ﬂare meter (LFM) (Kowa FM-700, Berkshire, UK)
without pupil dilatation. On each occasion, 10 readings with
a variation of less than 5% were taken. &e highest and
lowest values were discarded, and the remaining eight were
averaged to obtain the ﬂare measurement. Laser ﬂare values
were expressed in photon counts/millisecond (pc/ms) and
standard deviation (SD) was calculated. Calibration of the
laser ﬂare meter was performed according to the manual.
2.3. Statistical Analysis. For continuous variables, such as
IOP and anterior chamber ﬂare, the observed values were
summarized descriptively (mean± SD). Student’s two-group
paired t-test was used to determine the signiﬁcance of
between-group diﬀerences in IOP and anterior chamber
ﬂare. Association between IOP and ﬂare within each group
was analyzed using Pearson’s correlation coeﬃcient. Sta-
tistical signiﬁcance was declared at a type 1 error rate of
0.050. Statistical calculations and analyses were performed
using SAS for PC, version 9.3 (SAS Inc, Cary, NC).
3. Results
Fifty-six eyes of 28 ATTRV30M patients participated in this
analysis. Patients’ characteristics are shown in Figure 1 and
Table 1. In this study, highly statistical signiﬁcant diﬀerences
were found in the disorder in the BAB between the scalloped
iris eyes and the nonscalloped iris eyes (control). &e aqueous
humor ﬂare values in the eyes with a scalloped iris were
signiﬁcantly higher than those in the nonscalloped iris control
group (p< 0.001), while there were no signiﬁcant diﬀerences
in IOP between groups (p � 0.163) (Table 2; Figures 2 and 3).
&ere was no signiﬁcant correlation between the ﬂare and the
IOP values within groups (scalloped iris eyes group, Spear-
man-rho�−0.06, p � 0.749; nonscalloped iris eyes group
(control), Spearman-rho� 0.28, p � 0.135).
4. Discussion
&e present study demonstrated that the aqueous humor
ﬂare values were signiﬁcantly higher in the ATTRV30M
scalloped iris eyes than those in the nonscalloped iris eyes
(control group), and the IOP value was not signiﬁcantly
correlated with the increase in ﬂare in both groups.
We previously reported a strong association between
glaucoma and scalloped iris and advise to increase the
frequency of IOP surveillance and look for glaucoma in these
Table 1: Demographic and clinical data of ATTRV30M patients.
Characteristics ATTRV30Mpatients (n � 28)
Age, years 46.9± 5.6
Male/female 60.7%/39.3%
Time of ATTRV30M diagnosis, years 14.6± 3.9
Liver transplantation, % 96.4%
Time from liver transplantation, years 12.3± 3.4
Patients under tafamidis treatment, n 1
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eyes [20, 28]. Nevertheless, our study showed no signicant
increase in IOP and na increased protein concentration in
the aqueous humor in the scalloped iris eyes. ese results
may suggest the use of the are meter method for predicting
the risk of glaucoma in ATTRV30M scalloped iris eyes.
Several studies have addressed the changes to the
aqueous humor proteome in glaucoma using other tech-
niques with collection of aqueous humor samples after
and/or during surgery [11, 13–19]. Inoue et al. reported
higher levels of cytokines and growth factors in the aqueous
humor of open-angle glaucoma eyes using multiplex bead
immunoassay [13]. Imbalanced metabolism, lack of reactive
oxygen species detoxication, low-grade, and chronic
inammation in the aqueous humor of open-angle glau-
coma eyes were also assessed by several groups by mass
spectrometry [15–21].
e laser are meter is a precise, objective, and non-
invasive method that can reliably measure the function of the
BAB and the level of inammation [25, 31]. e increase in
aqueous are echoes a disruption of the BAB, which allows
leakage of serum proteins, as well as inammatory molecules
and cells, into the anterior segment by causing a change in
aqueous protein composition and concentration [13, 26].
Evaluation of the anterior aqueous are in patients with
glaucoma has also been addressed recently [27–29, 32].
Many groups have assessed the anterior chamber aqueous
(a) (b)
Figure 1: ATTRV30M scalloped iris eye (a) and the nonscalloped iris eye (control) (b) same patient.
Table 2: IOP and aqueous are values.
Parameters Scalloped iris Nonscalloped iris (control group) p value
Mean are (pc/ms) 14.1± 2.2 6.5± 0.9 p< 0.001
Mean IOP (mmHg) 17.1± 0.8 16.8± 0.7 p  0.163
p = 0.163
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Figure 2: IOP distribution of ATTRV30M patients with scalloped
iris and nonscalloped iris eyes (control).
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Figure 3: Aqueous are distribution of ATTRVM30 patients with
scalloped iris and nonscalloped iris eyes (control).
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ﬂare in glaucomatous eyes after treatment with anti-
glaucomatous drugs. Interestingly, Kahloun et al. used the
ﬂare meter to evaluate the anterior chamber aqueous ﬂare in
patients with pseudoexfoliation syndrome with or without
glaucoma and found that a high anterior aqueous ﬂare could
be a predictor for the development of glaucoma [27].
In our study, we observed an increased protein con-
centration in the aqueous humor of ATTRV30M patients
with scalloped iris eyes without IOP increased values. An
increase in protein concentration in the aqueous is the most
straightforward evidence for the breakdown of the BAB [25].
Some authors hypothesize that the breakdown of BAB
initially is due to endothelial injury caused by themutant TTR
[33, 34], but there must be another complementary mecha-
nism since patients are transplanted and have no TTRmutant
in circulation. &e damage should be from outside the vessels
were circulates the mutant TTR (aqueous humor and vitre-
ous). As ATTR V30M patients have a proinﬂammatory state
[35], we hypothesize that in response to this stimulation, the
ciliary pigmented epithelium may release a large variety of
cytokines and ﬁbrin aggregates which may induce the
breakdown of the BAB and outﬂow resistance in the anterior
segment of the eye in ATTRV30M patients. As described
previously, the intraocular production of TTR V30M by the
retinal and ciliary pigment epithelium remains unchanged in
these patients [8]. And the total aqueous humor TTR levels
are almost the same in liver transplanted and nontransplanted
ATTR V30M patients [10]. &us, we hypothesize that an
increased concentration of the unstable TTR V30M in pa-
tients’ eyes could also contribute to the breakdown of the BAB
and increased development of a mechanical barrier to the
outﬂow of the aqueous humor, resulting in IOP elevation and
worsening the prognostic for glaucoma development [30].
&erefore, anterior aqueous ﬂare measurements should
be considered in the staging and evaluation of the risk
progression to glaucoma and be considered as a marker of
ocular disease progression in ATTRV30M patients.&e ﬂare
cell meter may help us to objectify the action of a possible
treatment directed to the oculopathy and indirectly targeting
the central nervous system [36, 37]. Further, longitudinal
studies are warranted to assess the predictive value of
aqueous ﬂare for glaucoma development.
&is study had some limitations. Further analysis is
needed in order to determine which mediators are associated
with the breakdown of the BAB function in these ATTRV30M
patients. Furthermore, further histological or biochemical
analysis to determine whether the source of increased aqueous
ﬂare values resulted from the breakdown of the BAB itself or
simply from proteins diﬀusing from the posterior segment
caused by the breakdown of the blood-retinal barrier.
5. Conclusions
In this study, we found that the aqueous humor ﬂare value was
signiﬁcantly higher in the scalloped iris eyes than that in the
nonscalloped eyes in ATTRV30M patients without signiﬁcant
diﬀerences in IOP between groups. As a marker for in-
ﬂammation, and breakdown of the BAB, ﬂare values suggest
that controlling the stage and progression of glaucoma might
be key in the surveillance scalloped iris eyes in ATTRV30M
patients and may be considered as an evaluation method of
future treatments.
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